Souhaitez-vous accéder aux communiqués récents ?

Today, 25 March 2022, the Board of Directors of Hofseth BioCare ASA approved the Annual Report for 2021. Please find the Annual Report 2021 and ESG Report attached. For further information, please...

Hofseth BioCare (HBC) has been named Best Sustainable Biotech Company 2022 in the Global Health & Pharma Biotechnology Awards. The award is in recognition of HBC’s 15 years of pioneering research...

Hofseth BioCare (HBC) has been named Most Innovative Human Medical Nutrition Ingredients Producer in the ghp Technology Awards announced today. The award recognises the 15 years’ R&D and...

Hofseth BioCare ASA (“HBC”) had gross operating revenues of NOK 26.1m (23.1m) in the fourth quarter and total operating revenues of NOK 87.6m (69.3) for the full year. Cost of sales (CoGS) amounted to...

Roger Hofseth has today, 22 December 2021, bought 50,000 shares at an average price of approx. NOK 7.332 per share. Roger Hofseth is CEO and primary insider of Hofseth BioCare ASA. After the...

The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Friday 3 December 2021. The proposal for supplementary election of Amy...

Hofseth Biocare ASA is Now Part of an Exclusive Short-List of Companies to Have Successfully Obtained NDI Status for CalGo® and OmeGo® Nutritional Supplements Extracted from Norwegian Atlantic salmon....

Roger Hofseth has today, 18 November 2021, bought 55,000 shares at an average price of approx. NOK 7.25 per share. Roger Hofseth is CEO and primary insider of Hofseth BioCare ASA. After the...

An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the company’s premises in Kipervikgata 13, 6003 Ålesund on 3 December 2021 at 13:00 CET, for supplementary election to the Board...

As noted in the CEO Statement in our Q3 Financial Report issued today, 5 November 2021, Hofseth BioCare ASA (“HBC”) is a consumer and pet health ingredient supplier and an incubator for new drug...